Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2009
10/28/2009CN101564491A Chinese medicament for treating diabetic retinopathy
10/28/2009CN101564489A Process for extracting medicinal materials of Xiaotangling tablets
10/28/2009CN101564446A Total triterpene acid effervescent tablet of loquat leaf extraction
10/28/2009CN101564422A Chinese medicament for treating diabetic gout
10/28/2009CN101564409A Application of traditional Chinese indian lettuce in preparation of diabetes drugs
10/28/2009CN101564405A Application of total aglycone of himalayan teasel roots and single-component hederagenin in medicaments preparing Alpha-glucosidase inhibitor
10/28/2009CN101564399A Application of ophiopogonpolysaccharide MDG-1 in preparing medicament for treating diabetes mellitus
10/28/2009CN101564378A Levocarnitine oral solution and preparation method thereof
10/28/2009CN101564184A Maror and chrysanthemum beverage for reducing blood fat and weight
10/28/2009CN101564163A Food for reducing blood sugar and blood fat and preparation method thereof
10/28/2009CN101564161A Nutrition health food special for patients with hyperlipemia and hyperglycemia and preparation method thereof
10/28/2009CN101564160A Food for preventing and treating hyperlipemia and hyperglycemia and preparation method thereof
10/28/2009CN101564159A Food for reducing hypertension and diabetes and preparation method thereof
10/28/2009CN101564078A Health tea for reducing blood sugar and replenishing qi of mid-aged and old people
10/28/2009CN101564067A Green tea and ginger fat-reducing and weight-reducing beverage
10/28/2009CN100554268C Multicyclic compounds and the use as inhibitors of PARP, VEGFR2 and MLK3 enzymes
10/28/2009CN100554247C Muscarinic agonists
10/28/2009CN100553675C Process of preparing calcitonin microsphere
10/28/2009CN100553644C Composition containing pearl and vitamin and its use
10/28/2009CN100553641C Use of pachycladous algal onychin
10/28/2009CN100553631C Pharmaceutical uses of 4-fluoro-N-(1,2- hydrindenl-2-yl) benzamide
10/28/2009CN100553630C Controlled release formulation for oral administration of metformin
10/28/2009CN100553616C Medicine for treating diabetes
10/28/2009CN100553614C Preparation method of quickly disintegrating and dissolving solid medicine composition for oral cavity and its tablet
10/28/2009CN100553489C Production of sweet potato prandial fibre containing sweet-potato resistance starch
10/28/2009CN100553475C Feed additive containing the fruit of Chinese wolfberry
10/27/2009US7608718 4,5-dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity
10/27/2009US7608683 Human leukocyte antigen pan DR-binding peptides for use in the treatment of infections, inflammatory, autoimmune and cancer diseases; has heat shock protein that is capable of binding to MHC class II molecules
10/27/2009US7608634 Substituted pyrrolines as kinase inhibitors
10/27/2009US7608627 6-azaindole compound
10/27/2009US7608624 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives
10/27/2009US7608610 Transdermal formulation containing androgen, macrocyclic ester or ketone enhancer and thickener; extended time high blood serum concentration; rapidly absorbed gel; treatment of male hypogonadism
10/27/2009US7608609 Pharmaceutical composition
10/27/2009US7608608 Pharmaceutical composition
10/27/2009US7608607 Pharmaceutical composition
10/27/2009US7608606 Transdermal formulation containing androgen, macrocyclic ester or ketone enhancer and thickener; extended time high blood serum concentration; rapidly absorbed gel; treatment of male hypogonadism
10/27/2009US7608605 Transdermal formulation containing androgen, macrocyclic ester or ketone enhancer and thickener; extended time high blood serum concentration; rapidly absorbed gel; treatment of male hypogonadism
10/27/2009US7608577 Peptidyl ketones as inhibitors of DPIV
10/27/2009US7608452 Polynucleotides encoding cytokine receptor zcytor19
10/27/2009US7608284 Active enamel matrix substance, such as an amelogenin, a processed amelogenin product, or a metabolite can be used in treating conditions in a mammal which present an imbalance in its native immune resposne to external or internal stimuli
10/27/2009US7608245 Transmission and, or amplification of signal ; oral or enteric administering; dissolving; absorption by small inteestines; peptide yy; obesity therapy
10/27/2009CA2506441C 5-substituted-pyrazine or pyridine glucokinase activators
10/27/2009CA2466724C Benzamide and heteroarylamide as p2x7 receptor antagonists
10/27/2009CA2432713C Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
10/27/2009CA2422210C Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
10/27/2009CA2421826C Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
10/27/2009CA2415966C Tetrahydro-heterocycloazepinyl pyrimidine derivatives
10/27/2009CA2413798C Needle for intradermal delivery of substances having penetration limiting means
10/27/2009CA2376355C N-heterocyclic derivatives as nos inhibitors
10/27/2009CA2359454C ((aminoiminomethyl) amino) alkanecarboxamides and their applications in therapy
10/27/2009CA2338141C Polymer complexes of glucuronoglucanes
10/27/2009CA2320900C Biphasic controlled release delivery system for high solubility pharmaceuticals and method
10/27/2009CA2162366C Conjugation-stabilized polypeptide compositions
10/22/2009WO2009129036A1 Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
10/22/2009WO2009128734A1 Marker assisted identification of mammals for desired phenotypic trait
10/22/2009WO2009128713A1 Egg protein hydrolysates
10/22/2009WO2009128558A1 Activator for peroxisome proliferator-activated receptor
10/22/2009WO2009128543A1 Process for producing silica-containing tablet, tablet, and composite particle for tablet
10/22/2009WO2009128521A1 Cysteine protease inhibitor
10/22/2009WO2009128481A1 Nitrogenated 5-membered heterocyclic compound
10/22/2009WO2009128421A1 Hemifumarate of a pyrazole derivative
10/22/2009WO2009128360A1 Therapeutic agent for diabetes
10/22/2009WO2009127723A1 New arylsulphonylglycine derivatives, the preparation thereof and their use as medicaments
10/22/2009WO2009127686A1 Novel estrogen receptor ligands
10/22/2009WO2009127546A1 Pyrrolidinone glucokinase activators
10/22/2009WO2009127544A1 Pyridazinone glucokinase activators
10/22/2009WO2009127398A2 Conjugated linoleic acid derivatives
10/22/2009WO2009127321A1 Benzofurane, benzothiophene, benzothiazol derivatives as fxr modulators
10/22/2009WO2009127251A1 Combinations comprising a renin inhibitor
10/22/2009WO2009102428A3 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
10/22/2009WO2009100936A3 Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds, and the use thereof
10/22/2009WO2009099820A3 Modulating body weight
10/22/2009WO2009098490A9 Antimicrobial agents for the treatment of campylobacter species in the crop of a bird
10/22/2009WO2009093264A3 Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc.
10/22/2009WO2009046827A3 Use of growth hormone-releasing factor and/or mage-3 antigen (271-279) as therapeutic agents
10/22/2009WO2009043518A3 Use of a combination of cart peptides as a therapeutic agent
10/22/2009WO2009040050A3 Use of calcitonin as anti-angiogenic agent
10/22/2009WO2009039982A3 Use of gip alone or in combination with dynorphin b as a therapeutic agent
10/22/2009WO2009039972A3 Use of muramyl dipeptide (mdp) as a therapeutic agent
10/22/2009WO2009033810A3 Use of antioxidant peptide a (phckrm) and aplha-casein (90-96) as therapeutic agents in eg the treatment of hiv infection
10/22/2009US20090265798 Desaturase genes and uses thereof
10/22/2009US20090264529 Activators of peroxisome proliferator-activated receptors
10/22/2009US20090264515 Polynucleotide therapy
10/22/2009US20090264497 Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
10/22/2009US20090264476 CB-1 receptor modulator formulations
10/22/2009US20090264473 Novel Crystalline Forms of Antidiabetic Compounds
10/22/2009US20090264444 Organic compounds
10/22/2009US20090264442 Pyrazole derivatives as sigma receptor inhibitors
10/22/2009US20090264434 Pyridazinone glucokinase activators
10/22/2009US20090264428 Renin Inhibitors
10/22/2009US20090264424 Vanilloid receptor ligands and their use in treatments
10/22/2009US20090264422 Method of treating disease states using substituted pyrazole compounds
10/22/2009US20090264420 Organic compounds
10/22/2009US20090264418 such as [5-(4-cyclopentyl-piperazine-1-carbonyl)-1H-indol-2-yl]-pyrrolidin-1-yl-methanone, useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors
10/22/2009US20090264414 Amide Derivatives and Pharmaceutical Use Thereof
10/22/2009US20090264407 Substituted Sulfonamide Compounds
10/22/2009US20090264402 Novel diphenylazetidinone substituted by piperazine-1-sulfonic acid and having improved pharmacological properties
10/22/2009US20090264401 Substituted pyrimidin-5-carboxamides 281
10/22/2009US20090264376 Hoodia plant extract with improved flavor
10/22/2009US20090264369 Methods for reducing cd36 expression
1 ... 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 ... 1298